Jones Day

Abstract: This review article focuses on the interaction among certain scientific, legal, and regulatory aspects of pharmaceutical crystal forms. The article offers an analysis of pharmaceutical cocrystals as patentable inventions by drawing upon recent scientific developments in the field. Several potential commercial advantages of pharmaceutical cocrystals are highlighted, and a number of recent court decisions involving salient issues are summarized. The article provides an outlook on how the developing field of cocrystallization may impact the pharmaceutical intellectual property landscape. Keywords: Pharmaceutical; cocrystal; solid form; polymorph; intellectual property; patent; legal; regulatory

Abstract: Healthcare providers should revisit disaster response policies to incorporate telemedicine systems to address some of the unique challenges posed by infectious disease outbreaks such as coronavirus disease 2019 (COVID-19).

Abstract: Using institutional data on fall 1999 freshman admissions, we document the existence and magnitude of inequalities among California high schools in the access they provide to the University of California (UC). Because high schools are segregated by socioeconomic status and race, we examine how schools that differ on these dimensions also differ in their rates of admission to UC. We find that UC admission rates are grossly unequal between the public and private sectors and within each sector. Different groups, however, face different barriers. Schools where the student body is heavily Latino tend to have low per capita admissions because fewer students apply; schools where the student body is heavily African American tend to have low per capita admissions because fewer applicants are admitted. Our research suggests the need for both high school outreach to increase applications and contextual review of applications to reduce inequalities in the admission of applicants.

Abstract: Corporate governance activists have become increasingly critical of classified boards. This Article examines the arguments for and against the use of classified boards, arguing that their use is not necessarily inconsistent with good corporate governance. The Article begins by reviewing the legal framework surrounding classified board, focusing on applicable (i) state corporation statutes, (ii) directors' fiduciary duties, and (iii) federal securities laws. After a review of the debate over classified boards, the Article suggest that activists' general attacks on classified boards are misplaced and that these boards may be used effectively as part of a well-run corporate governance program.